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Abstract 
Two regioselective methods for the synthesis of nucleosides in the series of 3-phenyl- and 3-
ethoxycarbonyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones were developed. The first route 
involves a Vorbrüggen glycosylation reaction. The second one is based on condensation of 1,2,4-
triazolo[5,1-c][1,2,4]triazin-4-one sodium salts with protected 1-bromo-sugar derivatives. 
 
Keywords: 1,2,4-Triazolo[5,1-c][1,2,4]triazin-4-ones, glycosylation, NMR spectra,  
β-configuration, X-ray 
 
 
 
Introduction 
 
The synthesis of analogs of natural nucleosides based on modification of purines and 
pyrimidines is one of the most useful tools for development of antiviral compounds. In most 
cases, the structural transformations of nucleobases can be achieved by introduction or removal 
of different substituents. This methodology was successfully used for drug design of active 
antiviral agents: Brivudine [(E)-5-(2-bromovinyl)-2'-deoxyuridine], Idoxuridine (2'-deoxy-5-
iodouridine), Famciclovir (2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate).1-3 
 Another strategy for synthesis of antiviral compounds is based on isosteres of natural 
nucleobases or heterocycles containing fragments of purines or pyrimidines. 
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 This way have been applied for the synthesis of Marbavir (1-(β-L-ribofuranosyl)-2-
isopropylamino-5,6-dichlorobenzimidazole), Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide) and of its analogs.1,4-7 
 Herein, we report the synthesis of abnormal nucleosides in the series of 1,2,4-triazolo[5,1-
c][1,2,4]triazin-4-ones, considered as fused analogues of aza-isocytosines8 and exhibiting 
antiviral activity.9,10 
 
 
Results and Discussion 
 
The Vorbrüggen reaction is one of the widely used routes for the synthesis of nucleosides.11 This 
method of glycosylation involves interaction of protected sugar derivatives with appropriately 
silylated NH-heterocycles in the presence of a Lewis acid. 
We found that the conditions of the Vorbrüggen one-step method12 were useful for glycosylation 
of 1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones. Treatment on the NH-heterocycles 1a-e with N,O-
bis-(trimethylsilyl)acetamide (BSA) and trimethylsilyl triflate (TMSOTf) followed by addition 
of 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose at room temperature gave compounds 2a-e (Scheme 
1). Although there are three possible positions for N-glycosylation (N1, N6 or N8), only products 
of N-1 glycosylation were observed. The sugar fragments in 2a-e had exclusively the β-
configuration. 
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Scheme 1 
 
 Removing the protecting acetyls of the compounds 2a-c in sodium methoxide solution gave 
nucleosides 3a-c. Meanwhile the deacetylation of 2d,e was carried out in acidic medium by 
mixture ethanol with acetyl chloride. Attempts to remove the acetyl-protecting groups in 
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compound 2d,e by reaction with sodium ethoxide gave products of decomposition or incomplete 
deacetylation — for example, the monoacetyl derivative 4 was obtained from 2e. 
 The reaction of 1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones 1a-c with β-D-glucose penta-
acetate were carried out under the same conditions (BSA and TMSOTf) to give protected 
nucleoside 5a-c in 40-50% yield (Scheme 2).  
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Scheme 2 
 
 Following removal of the protection groups the nucleosides 6a-c were produced. The best 
conditions for deacetylation were found to be heating of 5a-c under reflux in MeONa/MeOH 
solution. 
 Reactions of purines and pyrimidine sodium salts with halogen derivatives of sugars provide 
an alternative nucleoside-forming methodology.13-16 Previously reported conditions for 
alkylation of azolo[5,1-c][1,2,4]triazin-4-ones sodium salts17 with halo-alkanes proved to be 
successful for the synthesis of nucleosides, too. Compounds 5a-c were obtained by the reaction 
of tetra-acetyl-α-D-bromoglucose and the sodium salt of 1,2,4-triazolo[5,1-c][1,2,4]triazinones 
7a-c, prepared from the heterocycles 1a-c in the presence of Na2CO3 (Scheme 3). 
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Scheme 3 
 
 The signals in both the 1H- and 13C- NMR spectra of compounds 2a-e and 5a-c were 
assigned using 2D- 1H, 1H COSY, 1H, 13C gHSQC and gHMBC experiments.  
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Figure 1. X-Ray crystal structure of compound 2e. 
 
 The position of the tri-O-acetyl-β-D-ribofuranosyl and tetra-O-acetyl-β-D-glucopyranosyl 
fragments at the N-1 atom of the 1,2,4-triazine part in compounds 2a-e and 5a-c are evident from 
the observed cross-peaks between H-1' and C-8a in the HMBC spectra. NOESY spectra of 2a-e 
showed the β-configuration of the furanoses due to the presence of correlation of peaks Н-1' with 
H-4'. The structure of the acetylated nucleoside 2d was confirmed by X-ray diffraction (Fig. 1). 
It was found that the ribofuranosyl fragment of 2d has a 3'-exo twist conformation. 
 The derivatives of glucopyranose, 5a-c, have a β-configuration, and this was also confirmed 
by 2D- gNOESY experiments showing cross-peaks H-1' with H-3' and H-5', and vicinal coupling 
constant of H-1'– H-2' (3J 9.0-9.5 Нz) in the 1H NMR.18 A single-crystal X-ray diffraction 
analysis was carried out in order to confirm the molecular structure of 5a-c. The molecular 
structure of 5c (Fig. 2) demonstrated that the glucopyranosyl fragment is attached at the azine 
part, and the sugar has the β-configuration. 
 The position of the protecting group in compound 4 has been determined by the 2D- HMBC 
spectrum, where the signal for the carbon of the acetyl group gave cross peaks with H-5'a and H-
5'b. The structures of the nucleosides 3a-e and 6a-c were confirmed by 1H NMR and mass 
spectra.  
 In conclusion, we have reported selective methods for synthesis of non- natural nucleosides 
based on 3-phenyl- and 3-ethoxycarbonyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones. 
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Figure 2. X-Ray crystal structure of compound 5b. 
 
 
Experimental Section  
 
General Procedures. IR spectra were recorded in KBr on a Perkin Elmer Spectrum One B FT-
IR instrument. The 1H- and 13C- NMR spectra were measured on Bruker WM-250, Bruker DRX-
400, and Bruker DRX-500 instruments. The 13C- and 1H- 2D NMR spectra were recorded on the 
Bruker DRX-500 spectrometer in DMSO-d6. The mass spectra were obtained using a quadrupole 
Shimadzu LCMS-2010 system with a Supelco LC-18 column (4.6 × 250 mm), where a 
temperature of 60 °C was maintained. The mobile phase was acetonitrile (100 %). Positive 
chemical APCI ionization in the selective ion-monitoring (SIM) mode was used. The capillary 
voltage was set at 1.5 kV and cone voltage at 15.0 V. Microanalyses were performed on a Perkin 
Elmer PE 2400 series II CHNS/O analyzer. TLC was carried out on Silufol UV-254 plates using 
ethyl acetate as the eluent; spots were visualized by exposure to UV radiation. Column 
chromatography was performed on Merck Kieselgel-60. 1-Bromo-2,3,5-tri-O-acetyl-α-D-
glucose, 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose, β-D-glucose penta-acetate, N,O-bis-
(trimethylsilyl)acetamide and trimethylsilyl triflate were purchased from Aldrich. RT denotes 
room temperature. 
 
1,2,4-Triazolo[5,1-c][1,2,4]triazin-4(6H)-ones (1a-e) was prepared according to the procedure 
described earlier.19,20 
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1-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones (2a-e). 
N,O-Bis-(trimethylsilyl)acetamide (0.328 mL, 1.34 mmol), trimethylsilyl triflate (TMSOTf) 
(0.32 mL, 1.8 mmol) and 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (0.28 g, 0.90 mmol) were 
added to a solution of compound (1a-e) (0.94 mmol) in 5 ml acetonitrile. The reaction mixture 
was left at RT for 2.5 h, diluted with 10 ml acetonitrile with a few drops of water and neutralized 
with NaHCO3. The resulting suspension was filtered. The filtrate was concentrated in vacuo. The 
product was isolated by column chromatography using ethyl acetate: hexane (4:1) as the eluent. 
Compound 2a. Yield 0.20 g (45 %); mp 73 °С; [α]20D -56.5º (c 1.0, EtOAc); MS (APCI, m/z 
(rel. %)) 472 (100%) [M+H]+; IR: CO 1721, 1745; 1Н NMR (DMSO-d6): δ 1.78 (s, 3H, Me of 5'-
Ac), 2.09 (s, 3H, Me of 3'-Ac), 2.11 (s, 3H, Me of 2'-Ac), 4.16 (d,d, 1H, H-5'b, J=5.0 Hz, J=12.5 
Hz) 4.37 (d,d, 1H, H-5'a, J=3.2 Hz, J=12.3 Hz), 4.46 (m, H-4'), 5.67 (t, 1H, H-3', J=5.5 Hz), 
5.91 (d,m, 1H, H-2', J=5.3 Hz), 6.49 (d, 1H, H-1', J=3.0 Hz), 7,54 (m, 3H, m, p-Ph), 8.06 (m, 
2H, o-Ph), 8.43 (s, 1H, H-7); 13C NMR (DMSO-d6): δ 19.93 (Me of 5'-Ac), 20.08 (Me of 2'-Ac + 
Me of 3'-Ac), 62.30 (C-5'), 69.73 (C-3'), 72.41 (C-2'), 79.06 (C-4'), 91.38 (C-1'), 128.13 (C-m), 
128.55 (C-o), 129.98 (C-p), 131.70 (C-i), 140.58 (C-3), 148.65 (C-4), 150.61 (C-8a), 152.86 (C-
7), 169.03 (CO of 2'-Ac), 169.27 (CO, of 3'-Ac), 169.72 (CO of 5'-Ac). Calc. for C21H21N5O8: C, 
53.50; H, 4.49; N, 14.86. Found: C, 54.02; H, 4.51; N, 14.20%. 
Compound 2b. Yield 0.22 g (48 %); mp 173 оС; [α]20D -53.4º (c 1, EtOAc); MS (APCI, m/z 
(rel. %)) 486 (100%) [M+H]+; IR: CO 1770, 1721; 1Н NMR (DMSO-d6): δ 1.78 (s, 3H, (Me of 
5'-Ac), 2.10 (s, 3H, (Me of 3'-Ac), 2.12 (s, 3H, (Me of 2'-Ac), 2.45 (s, 3H, Me), 4.16 (d,d, 1H, H-
5'b, J=5.0 Hz, J=12.5 Hz) 4.36 (d,d, 1H, H-5'a, J=3.0 Hz, J=12.3 Hz), 4.46 (m, H-4'), 5.66 (t, 
1H, H-3', J=5.5 Hz), 5.91 (d,m, 1H, H-2', J=5.3 Hz), 6.45 (d, 1H, H-1', J=2.5 Hz), 7.52 (m, 3H, 
m-H-, p-Ph), 8.06 (m, 2H, o-Ph); 13C NMR (DMSO-d6): δ 14.02 (Me), 19.93 (Me of 5'-Ac), 
20.09 (Me of 2'-Ac + Me of 3'-Ac), 62.31(C-5'), 69.78(C-3'), 72.34(C-2'), 79.06 (C-4'), 91.15 (C-
1'), 128.12 (Cm), 128.53 (Co), 129.96 (Cp), 131.78 (Ci), 140.58 (C-3), 148.16 (C-4), 150.83 (C-
8a), 162.51 (C-7), 169.06 (CO of 2'-Ac), 169.30 (CO of 3'-Ac), 169.73 (CO of 5'-Ac). Calc. for 
C22H23N5O8: C, 54.43; H, 4.78; N, 14.43. Found: C, 54.06; H, 4.80; N, 14.22%. 
Compound 2c. Yield 0.24 g (50 %); mp 121 оС; [α]20 D -38.3º (c 1, EtOAc); MS (APCI, m/z 
(rel. %)) 518 (100%) [M+H]+, 519 (32.7%) [M+1+H]+, 520 (6.7%) [M+2+H]+; IR: CO 1711 
1747; 1Н NMR (DMSO-d6): δ 1.78 (s, 3H, Me of 5'-Ac), 2.10 (s, 3H, Me of 3'-Ac), 2.12 (s, 3H, 
Me of 2'-Ac), 2.67 (s, 3H, SMe), 4.15 (d,d, 1H, H-5'b), J=5.0 Hz, J=12.5 Hz) 4.36 (d,d, 1H, H-
5'a), J=3.5 Hz, J=12.5 Hz), 4.46 (m, H-4'), 5.67 (t, 1H, H-3', J=5.5 Hz), 5.89 (d,m, 1H, H-2' 
J=5.0 Hz), 6.40 (d, 1H, H-1', J=2.5 Hz), 7,52 (m, 3H, m-, p-Ph), 8.05 (m, 2H, o-Ph);13C NMR 
(DMSO-d6): δ 13.40 (SMe), 19.93 (Me of 5'-Ac), 20.08 (Me of 2'-Ac + Me of 3'-Ac), 62.28(C-
5'), 69.70 (C-3'), 72.33 (C-2'), 79.04 (C-4'), 91.35 (C-1'), 128.13 (C-m), 128.52 (C-o), 130.05 (C-
p), 131.66 (C-i), 140.98 (C-3), 147.34 (C-4), 151.11 (C-8a), 165.33 (C-7), 169.02 (CO of 2'-Ac), 
169.27 (CO of 3'-Ac), 169.50 (CO of 5'-Ac). Calc. for C22H23N5O8S: C, 51.06; H, 4.48; N, 13.53. 
Found: C, 51.22; H, 4.48; N, 13.63%. 
Compound 2d. Yield 0.20 g, (46 %); mp 127 оС; [α]20D -75.9º (c 1, EtOAc); MS (APCI, m/z 
(rel. %)) 468 (100%) [M+H]+; IR: CO 1759, 1744; 1Н NMR (CDCl3): δ 1.41 (t, 3H, Me of OEt), 
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2.03 (s, 3H, Me of 5'-Ac), 2.11 (s, 6H, Me of 3'-Ac + Me of 2'-Ac), 4.26 (d,d, 2H, H-5b', J=6.0 
Hz, J=12.0 Hz), 4.39 (d,d, 2H, H-5a', J=3.5 Hz, J=12.2 Hz), 4.36-4.48 (m, 3H, (CH2 of OEt + 
H-4'), 5.63 (t, 1H, H-3', J=5.5 Hz), 5.83 (m, 1H, H-2'), 6.54 (d, 1H, H-1', J=3.0 Hz), 8.17 (s, 1H 
H-7). 13C NMR (CDCl3): δ 13.99 (Me of OEt); 20.34 (Me of 5'-Ac), 20.39 (Me of 2'-Ac), 20.54 
(Me of 3'-Ac), 63.02 (OCH2 + C-5'), 70.60 (C-3'), 73.07 (C-2'), 80.92 (C-4'), 93.26 (C-1'), 
133.19 (C-3), 145.61 (C-4), 150.27 (C-8a), 153.36 (C-7),159.52 (CO), 169.56 (CO of 2'-Ac + 
CO of 3'-Ac), 170.35 (CO of 5'-Ac). Calc. for C18H21N5O10: C, 46.26; H, 4.53; N, 14.98. Found: 
C, 46.13; H, 4.54; N, 14.78%. 
Compound 2e. Yield 0.19 g, (42 %); mp 153 оС; [α]20D -60.3º (c 1, EtOAc); MS (APCI, m/z 
(rel. %)) 482 (100%) [M+H]+; IR: CO 1751, 1758; 1Н NMR (CDCl3): δ 1.20 (t, 3H, Me of OEt), 
2.04 (s, 3H, Me of 5'-Ac), 2.12 (s, 6H, Me of 3'-Ac + 2'-Ac), 2.55 (s, 3H, Me), 4.26 (d,d, 2H, H-
5b', J=6.0 Hz, J=12.3 Hz), 4.39 (d,d, 2H, H-5a', J=3.5 Hz, J=12.3 Hz), 4.41-4.49 (m, 3H, CH2 
of OEt + H-4'), 5.65 (t, 1H, H-3', J=5.0 Hz), 5.87 (m, 1H, H-2'), 6.52 (d, 1H, H-1', J=3.0 Hz); 
13C NMR (CDCl3): δ 13.99 (Me of OEt), 14.61 (Me), 20.36 (Me of 5'-Ac), 20.40 (Me of 2'-Ac) 
20.54 (Me of 3'-Ac), 62.98 (OCH2 + C-5'), 70.62 (C-3'), 72.93 (C-2'), 81.43 (C-4'), 92.93 (C-1'), 
133.20 (C-3), 145.37 (C-4), 150.39 (C-8a), 159.65 (CO), 164.37 (C-7), 169.37 (CO of 2'-Ac + 
CO of 3'-Ac), 170.34 (CO of 5'-Ac). Calc. for C19H23N5O10: C, 47.40; H, 4.82; N, 14.55. Found: 
C, 47.06; H, 4.92; N, 14.31%. 
1-(β-D-Ribofuranosyl)-3-phenyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones (3a-c). Compound 
(2a-c) (0.4 mmol) was added to a sodium methoxide solution, which was prepared from sodium 
(0.03 g, 1.30 mmol) and methanol (4 ml). The reaction mixture was refluxed for 0.5 h, cooled, 
neutralized acetic acid and concentrated in vacuo. The product was isolated by column 
chromatography using ethyl acetate as the eluent. 
Compound 3a. Yield 0.082 g, (57%); mp 216 оС; [α]20D -55.1º (c 0.3, MeCN); MS (APCI, m/z 
(rel. %)) 346 (100%) [M+H]+; IR: CO 1717; 1Н NMR (DMSO-d6): δ 3.26-3.53 (m, 1H, H-5'b), 
3.61-3.66 (m, 1H, H-5'a), 3.97 (q, 1H, H-4', J = 5.5 Hz), 4.36 (q, 1H, H-3', J=6.0 Hz), 4.65 (m, 
1H, OH), 4.67 (m, 1H, H-2'), 5.21 (d, 1H, OH, J=6.0 Hz), 5.55 (d, 1H, OH, J=4.8 Hz), 6.25 (d, 
1H, H-1'. J=2.8 Hz), 7.53 (m, 3H, m-, p-Ph), 8.00 (m, 2H, o-Ph), 8.46 (s, 1H, H-7). Calc. for 
C15H15N5O5·H2O: C, 49.59; H, 4.72; N, 19.28. Found: C, 49.31; H, 4.73; N, 19.62%. 
Compound 3b. Yield 0.101 g, (65%); mp 210 оС; [α]20D -52.9º (c 0.2, EtOAc); MS (APCI, m/z 
(rel. %)) 360 (100%) [M+H]+;1Н NMR (DMSO-d6): δ 2.48 (s, 3H, Me), 3.48-3.55 (m, 1H, H-
5'b), 3.60-3.66 (m, 1H, H-5'a), 3.95 (q, 1H, H-4', J=4.5 Hz), 4.36 (q, 1H, H-3', J=5.5 Hz), 4.53 
(m, 1H, OH), 4.66 (m, 1H, H-2'), 5.20 (d, 1H, OH, J=6.2 Hz), 5.55 (d, 1H, OH, J=4.2 Hz), 6.19 
(d, 1H, H-1', J=2.8 Hz), 7.53 (m, 3H, m-, p-Ph), 8.01 (m, 2H, o-Ph); Calc. for C16H17N5O5·H2O: 
C, 50.93; H, 5.08; N, 18.56. Found: C, 51.30; H, 4.77; N, 18.64%. 
Compound 3c. Yield 0.099 g (61%); mp 167 оС [α]20D -61.4º (c 0.5, MeCN); MS (APCI, m/z 
(rel. %)) 392 (100%) [M+H]+, 393 (19.5%) [M+1+H]+, 394 (9.0%) [M+2+H]+. IR: CO, 1727cm-
1; 1Н NMR (DMSO-d6): δ 2.66 (s, 3H, SMe), 3.47-3.52 (m, 1H, H-5'b), 3.61-3.65 (m, 1H, H-5'a), 
3.96 (q, 1H, H-4', J=4.5 Hz), 4.34 (q, 1H, H-3', J=5.0 Hz), 4.50-4.56 (m, 2H, OH + H-2'), 4.99 
(d, 1H, OH, J=6.0 Hz), 5.30 (d, 1H, OH, J=5.0 Hz), 6.19 (d, 1H, H-1', J=3.5 Hz), 7.48 (m, 3H, 
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m-, p-Ph), 8.03 (m, 2H, o-Ph); Calc. for C16H17N5O5S·H2O: C, 46.94; H, 4.68; N, 17.11. Found: 
C, 46.50; H, 4.49; N, 17.19%. 
1-(β-D-Ribofuranosyl)-3-ethoxycarbonyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones (3d,e). 
Compound 2d or 2e (0.4 mmol) was added to a solution of HCl prepared from anhydrous 
ethanol (10 mL) and acetyl chloride (2 mL). The resulting solution was kept at r.t. for 48 h, then 
neutralized with AcONa and evaporated in vacuo. The product was isolated by column 
chromatography using ethyl acetate: hexane (3:1) as the eluent. 
Compound 3d. Yield 0.02 g, (15%); mp 183 оС, [α]20D -64.2º (c 0.3, MeCN); MS (APCI, m/z 
(rel. %)) 342 (100%) [M+H]+; IR: CO 1742, 1710; 1Н NMR (DMSO-d6): δ 1.40 (t, 3H, Me of 
OEt), 3.50-3.55 (m, 1H, H-5'b), 3.57-3.64 (m, 1H, H-5'a), 4.02 (q, 1H, H-4', J=4.2 Hz), 4.22 (q, 
1H, H-3', J=4.2 Hz), 4.37-4.50 (m, 4H, OCH2 of OEt + H-2' + OH), 4.93 (d, 1H, OH, J=6.0 Hz), 
5.28 (d, 1H, OH, J=5.0 Hz), 6.19 (d, 1H, H-1', J=3.5 Hz), 8.17(s, 1H, H-7). Calc. for 
C12H15N5O7: C, 42.23; H, 4.43; N, 20.52. Found: C, 42.17; H, 5.00; N, 19.98%. 
Compound 3e. Yield 0.017 g, (12%); mp 108 оС; [α]20D -42.9º (c 0.3, MeCN); MS (APCI, m/z 
(rel. %)) 356 (100%) [M+H]+; IR: CO 1741, 1707; 1Н NMR (DMSO-d6): δ 1.40 (t, 3H, Me of 
OEt), 2.49 (s, 3H, Me), 3.51-3.55 (m, 1H, H-5'b), 3.60-3.64 (m, 1H, H-5'a), 4.02 (q, 1H, H-4', 
J=3.7 Hz), 4.25-4.32 (m, 1H, H-3'), 4.37-4.50 (m, 4H, OCH2 of OEt + H-2' + OH), 4.93 (d, 1H, 
OH, J=5.0 Hz), 5.27 (d, 1H, OH, J=3.7 Hz), 6.14 (d, 1H, H-1', J=3.3 Hz). Calc. for C13H17N5O7: 
C, 43.95; H, 4.82; N, 19.71. Found: C, 43.80; H, 5.01; N, 19.98%. 
1-(5'-O-Acetyl-β-D-ribofuranosyl)-3-ethoxycarbonyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-
one (4). Compound (2e) (0.19 g, 0.4 mmol) was added to a sodium methoxide solution, which 
was prepared from sodium (0.005 g, 0.022 mmol) and anhydrous ethanol (15 mL). The reaction 
mixture was kept at r.t. for 0.25 h, cooled, neutralized with acetic acid and concentrated in vacuo. 
The product was isolated by column chromatography using ethyl acetate: hexane (7:1) as the 
eluent. Yield: 0.087 g, (55%); mp 92 оС; [α]20D -31.3º (c 0.5, MeCN); MS (APCI, m/z (rel. %)) 
398 (100%) [M+H]+; IR: CO 1744, 1732, 1706; 1Н NMR (CDCl3): δ 1.41 (t, 3H, Me of OEt), 
2.05 (s, 3H, Me of OAc), 2.53 (s, 3H, Me), 3.35 (br. s, 1H, OH), 4.03 (br. s, 1H, OH), 4.27 (d,d, 
2H, H-5b', J=6.5 Hz, J=11.7 Hz), 4.27 (d,d, 2H, H-5a', J=3.5 Hz, J=11.0 Hz), 4.40-4.46 (m, 3H, 
CH2 of OEt + H-4'), 4.55 (t, 1H, H-3', J=5.0 Hz), 4.78 (d, 1H, H-2', J=4.0 Hz), 6.47 (d, 1H, H-1', 
J=2.0 Hz). 13C NMR (CDCl3): δ 14.04 (CH3 of OEt), 14.53 (Me), 20.65 (Me of Ac), 63.01 (CH2 
of OEt), 63.95 (C-5'), 71.31 (C-3'), 73.72 (C-2'), 82.84 (C-4'), 95.22 (C-1'), 132.55 (C-3), 145.67 
(C-4), 150.90 (C-8a), 160.20 (CO), 164.61 (C-7), 171.10 (CO of Ac). Calc. for C15H19N5O8: C, 
45.34; H, 4.82; N, 17.63. Found: C, 45.55; H, 5.03; N, 17.26%. 
1-(2',3',4',5'-Tetra-O-acetyl-β-D-glucopyranosyl)-3-phenyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-
4-ones (5a-c). Method A.. N,O-bis-(Trimethylsilyl)acetamide (0.328 ml, 1.34 mmol), 
trimethylsilyl triflate (TMSOTf) (0.32 ml, 1.8 mmol) and β-D-glucose penta-acetate (0.39 g, 1.00 
mmol) were added to a solution of compound (1a-c) (0.94 mmol) in 7 mL acetonitrile. The 
reaction mixture was left at r.t. for 2.5 h, diluted with 10 mL acetonitrile with a few drops water, 
and neutralized (NaHCO3). The resulting suspension was filtered, the filtrate concentrated in 
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vacuo, and the product isolated by column chromatography using ethyl acetate: hexane (3:1) as 
the eluent. 
Method B. Compound (1a-c) (0.94 mmol) was suspended in a 17% sodium carbonate solution 
(3 mL). The precipitate was filtered off and dried. The resulting solid was dissolved in DMF (5 
mL), acetobromo-α-D-glucose (0.390 g, 0.95 mmol) was added, and the mixture was heated on a 
water bath for 3 h. Then the reaction mixture was concentrated in vacuo. The product was 
isolated by column chromatography using ethyl acetate: hexane (3:1) as eluent. 
Compound 5a. Yield of (A) 0.23 g, (45%); of B 0.15g, (30%); mp 184 оС; [α]20D -37.4º (c 0.3, 
MeCN); MS (APCI, m/z (rel. %)) 544 (100%) [M+H]+; IR: CO 1749, 1724; 1Н NMR (DMSO-
d6): δ 1.97 (s, 3H, Me of 2'-Ac), 2.00 (s, 3H, Me of 6'-Ac), 2.01 (s, 3H, Me of 3'-Ac), 2.03 (s, 3H, 
Me of 4'-Ac), 4.04 (d,d, 1H, H-6'b, J=2 Hz,  J=12 Hz), 4.19 (d,d, 1H, H-6'a, J=5.0 Hz, J=12.5 
Hz), 4.47 (m, 1H, H-5'), 5.08 (t, 1H, H-4', J=10.0 Hz), 5.69 (t, 1H, H-3', J=9.5 Hz), 5.89 (t, 1H, 
H-2', J=9.5 Hz), 6.50 (d., 1H, H-1', J=9.0 Hz), 7,53 (m, 3H, m-,p-Ph), 8.01 (m, 2H, o-Ph), 8.45 
(s, 1H, H-7). 13C NMR (DMSO-d6): δ 20.08 (Me of Ac), 20.15 (Me of Ac + Me of Ac), 20.25 
(Me of Ac), 61.43 (C-6'), 67.44 (C-2' + C-4'), 72.60 (C-3'), 72.94 (C-5'), 85.00 (C-1'), 128.00 
(Cm), 128.80 (Co), 129.90 (Cp), 131.69 (Ci), 141.50 (C-3), 148.50 (C-4), 151.10 (C-8a), 152.85 
(C-7), 168.64 (CO of 2'-Ac), 169.06 (CO of 4'-Ac), 169.34 (CO of 3'-Ac), 169.91 (CO of 6'-Ac). 
Calc. for C24H25N5O10·H2O: C, 52.84; H, 4.99; N, 12.84. Found: C, 52.41; H, 4.62; N, 11.99%. 
Compound 5b. Yield of (A) 0.25 g, (48%); of (B) 0.17 g, (33%). mp 243 оС; [α]20D -35.5º (c 
0.3, MeCN); MS (APCI, m/z (rel. %)) 558 (100%) [M+H]+; IR: CO 1746, 1735; 1Н NMR 
(DMSO-d6): δ 1.85 (s, 3H, Me of 2'-Ac), 1.95 (s, 3H, Me of 6'-Ac), 1.97 (s, 3H, Me of 3'-Ac), 
2.02 (s, 3H, Me of 4'-Ac), 2.47 (s, 3H, Me), 4.02 (d,x m, 1H, H-6'b, J=12.0 Hz), 4.20 (d,d, 1H, 
H-6'a, J=4.5 Hz, J=12.7 Hz), 4.48 (m, 1H, H-5'), 5.07 (t, 1H, H-4', J=9.5 Hz), 5.68 (t, 1H, H-3', 
J=10.0 Hz), 5.87 (t, 1H, H-2', J=9.5 Hz), 6.53 (d, 1H, H-1', J=9.0 Hz), 7,52 (m, 3H, m-,p-Ph), 
7.99 (m, 2H, o-Ph). 13C NMR (DMSO-d6): δ 14.18 (Me), 20.21 (Me of Ac), 20.30 (Me of Ac + 
Me of Ac), 20.39 (Me of Ac), 61.39 (C-6'), 67.39 (C-2' + C-4'), 72.61 (C-3'), 72.90 (C-5'), 84.72 
(C-1'), 128.10 (Cm), 128.89 (Co), 139.98 (Cp), 131.88 (C-i), 140.78 (C-3), 148.24 (C-4), 151.28 
(C-8a), 162.51 (C-7), 168.79 (CO of 2'-Ac), 169.19 (CO of 4'-Ac), 169.45 (CO of 3'-Ac), 169.88 
(CO of 6'-Ac). Calc. for C25H27N5O10: C, 53.86; H, 4.88; N, 12.56. Found: C, 53.81; H, 4.50; N, 
12.43%. 
Compound 5c. Yield of (A) 0.28 g, (50%); of (B) 0.22g, (40%); mp 224 оС; [α]20D -25.9º (c 0.5, 
MeCN); MS (APCI, m/z (rel. %)) 590 (100.0%) [M+H]+, 591 (27.0%) [M+1+H]+, 592 (12.37%) 
[M+1+H]+; IR, CO 1750, 1720; 1Н NMR (DMSO-d6): δ 1.96 (s, 3H, Me of 2'-Ac), 1.97 (s, 3H, 
Me of 6'-Ac), 2.01 (s, 3H, Me of 3'-Ac), 2.02 (s, 3H, Me of 4'-Ac), 2.68 (s, 3H, SMe), 4.02 (d x 
m, 1H, H-6'b, J=12 Hz), 4.16 (dd, 1H, H-6'a, J=4.5 Hz, J=12 Hz), 4.46 (m, 1H, H-5'), 5.07 (t, 
1H, H-4', J=9.5 Hz), 5.67 (t, 1H, H-3', J=9.5 Hz), 5.85 (t, 1H, H-2', J=9.0 Hz), 6.50 (d., 1H, H-1', 
J=9.5 Hz), 7,52 (m, 3H, m-, p-Ph), 7.99 (m, 2H, o-Ph); 13C NMR (DMSO-d6): δ 13.51 (SMe), 
20.21 (Me of Ac), 20.32 (Me of Ac + Me of Ac), 20.40 (Me of Ac), 61.48 (C-6'), 67.39 (C-2' + 
C-4'), 72.60 (C-3'), 72.96 (C-5'), 84.70 (C-1'), 128.14 (Cm), 128.80 (Co), 130.12 (Cp), 131.79 
(Ci), 141.24 (C-3), 147.45 (C-4), 151.70 (C-8a), 165.35 (C-7), 168.84 (CO of 2'-Ac), 169.22 
Issue in Honor of Prof Henk C. van der Plas ARKIVOC 2009 (vi) 196-207 
ISSN 1551-7012 Page 205 ©ARKAT USA, Inc. 
(CO of 4'-Ac), 169.50 (CO of 3'-Ac), 169.91(CO of 6'-Ac). Calc. for C25H27N5O10S: C, 50.93; H, 
4.62; N, 11.88. Found: C, 50.81; H, 4.62; N, 11.67%. 
1-(β-D-Glucopyranosyl)-3-phenyl-1,2,4-triazolo[5,1-c][1,2,4]triazin-4-ones (6a-c). Compound 
(5a-c) (0.4 mmol) was added to a sodium methoxide solution, prepared from sodium (0.03 g, 
1.30 mmol) and methanol (5 ml). The reaction mixture was heated at reflux for 0.5 h, cooled, 
neutralized with acetic acid and concentrated in vacuo. The product was isolated by column 
chromatography using ethyl acetate as the eluent. 
Compound 6a. Yield 0.076 g, (48%); mp 211 оС; [α]20D 2.9º (c 0.3, MeCN); MS (APCI, m/z 
(rel. %)) 376 (100%) [M+H]+. IR: CO, 1717 cm-1. 1H NMR (DMSO-d6): δ 3.25-3,34 (m, 1H, H-
6'b), 3.34-3.57 (m, 3H, H-6'a + H-5' + H-4'), 3.69-3.76 (m, 1H, H-3'), 4.07 (m, 1H, H-2'), 4.39 (t, 
1H, OH, J=5.7 Hz), 5.03 (d, 1H, OH, J=5.2 Hz), 5.15 (d, 1H, OH, J=4.7 Hz), 5.25 (d, 1H, OH, 
J=4.5 Hz), 5.70 (d, 1H, H-1', J=8.3 Hz), 7,50 (m, 3H, m-, p-Ph), 8.03 (m, 2H, o-Ph), 8.30 (s. 1H, 
H-7). Calc. for C16H17N5O6·H2O: C, 48.86; H, 4.87; N, 17.80. Found: C, 48.24; H, 4.84; N, 
17.28%. 
Compound 6b. Yield 0.099 g, (64%); mp 237 ºC; [α]20D 30.5º (c 0.5, DMSO); MS (APCI, m/z 
(rel. %)) 390 (100%) [M+H]+. IR: CO 1717cm-1. 1H NMR (DMSO-d6): δ 2.48 (s, 3H, Me), 3.23-
3,36 (m, 1H, H-6'b), 3.40-3.54 (m, 3H, H-6'a + H-5' + H-4'), 3.69-3.73 (m, 1H, H-3'), 4.05 (m, 
1H, H-2'), 4.27 (t, 1H, OH, J=5.0 Hz), 4.92 (br. s, 1H, OH), 5.02 (br. s, 1H, OH), 5.18 (br. s, 1H, 
OH), 5.67 (d, 1H, H-1', J=8.7 Hz), 7,48 (m, 3H, m-, p-Ph), 8.04 (m, 2H, o-Ph). Calc. for 
C17H19N5O6: C, 52.44; H, 4.92; N, 17.99. Found: C, 52.19; H, 4.91; N, 18.04%. 
Compound 6c. Yield 0.053 g, (30%); mp 258 оС; [α]20D 3.5º (c 0.1, MeCN); MS (APCI, m/z 
(rel. %)) 422 (100%) [M+H]+, 423 (26.6%) [M+1+H]+, 424 (10.5%) [M+2+H]+. IR: CO 1718; 
1H NMR (DMSO-d6): δ 2.68 (s, 3H, SMe), 3.22-3,34 (m, 1H, H-6'b), 3.39-3.52 (m, 3H, H-6'a + 
H-5' + H-4'), 3.69-3.73 (m, 1H, H-3'), 4.07 (m, 1H, H-2'), 4.25 (t, 1H, OH, J=5.2 Hz), 4.92 (d, 
1H, OH, J=5.2 Hz), 5.02 (d, 1H, OH, J=5.0 Hz), 5.18 (d, 1H, OH, J=4.5 Hz), 5.70 (d, 1H, H-1', 
J=9.0 Hz), 7,50 (m, 3H, m-, p-Ph), 8.03 (m, 2H, o-Ph). Calc. for C17H19N5O6S.H2O: C, 46.46; H, 
4.82; N, 15.94. Found: C, 46.70; H, 4.79; N, 15.20%. 
X-Ray data collection and structure refinement. Data collection for compound 2e 
(crystallized from 2-propanol) was carried out using a Bruker SMART 1000 CCD diffractometer 
using graphite- monochromated Mo-Kα (λ = 0.71073 Å). X-ray data of blocked nucleoside 5c 
(crystallized from acetic acid) were collected on CAD4 Enraf-Nonius graphite-monochromated 
Mo-Kα (λ = 0.71073 Å). All calculations were carried out the SHELXTL program package.21 A 
summary of the fundamental crystal and refinement date is given in Table 1. Crystallographic 
data for 2e and 5b have been deposited at Cambridge Crystallographic Date Centre. The CCDC 
numbers are listed in Table 1. Copies of the date can be obtained free of charge upon application 
to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK: FAX: +44 (1223) 336033, e-mail: 
deposit@ccdc.cam.ac.uk. 
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Table 1. Crystal date and structure refinement for compounds 2e and 5c 
Crystal Data 2e 5c 
Identification code CCDC-720052 CCDC-720053 
Empirical formula C19H23N5O10 C25H27N5O10 
Formula weight 481.42 557.52 
Temperature (K) 120(2) 293(3) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Orthorhombic Orthorhombic 
Space group P 21 21 2 P 21 21 22 
Unit cell dimension a (Å) 16.3319(15) a (Å) 10.715(2) 
 b (Å) 16.6892(15) b (Å) 11.172(2) 
 c (Å) 8.1038(8) c (Å) 21.733(4) 
 α (º) 90.00 α (º) 90.00 
 β (º) 90.00 β (º) 90.00 
 γ (º) 90.00 γ (º) 90.00 
Volume (Å3) 2208.8(4) 2601.6(8) 
Z 4 4 
Density (calculated) (mg/m3) 1.448 1.423 
Absorption coefficient 0.119 0.112 
F(000) 1008 1.002 
Theta range (º) 1.74 to 27 1.87 to 26.99 
Index ranges -20<=h<=19 0<=h<=13 
 -21<=k<=21 0<=k<=14 
 -10<=k<=10 -3<=k<=27 
Reflection collected 18615 3210 
Independent reflection 4814 [R(int)=0.0575] 3173[R(int)=0.0549] 
Completeness to theta (º) 99.7% 99.1% 
Date/ restraints/ parameters 4814 / 0 / 312 3173 / 0 / 366 
Goodness-of-fit on F2 1.037 1.002 
R [I>2sigma(I)] 0.0342(3676 reflns.) 0.0434 (1311 reflns.) 
RwF (all data) 0.0589 0.0921 
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